Scoring of reflux symptoms associated with scleroderma and the usefulness of rabeprazole

Clinical and Experimental Rheumatology

Volumn 27, Issue 3 SUPPL. 54, 2009, Pages

  Muro, Yoshinao ^a   Sugiura, Kazumitsu ^a   Nitta, Yukiko ^b   Mitsuma, Teruyuki ^c   Hoshino, Kei ^c   Usuda, Toshikazu ^d   Hayashi, Kaori ^d   Murase, Yumi ^d   Shimizu, Makoto ^e   Matsuo, Hiromi ^e  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

^c Ichinomiya Municipal Hospital   (Japan)

^d CHUKYO HOSPITAL   (Japan)

^e NAGOYA EKISAIKAI HOSPITAL   (Japan)

Author keywords

Gastroesophageal reflux disease; Medical questionnaire; Proton pump inhibitors; Rabeprazole; Scleroderma

Indexed keywords

RABEPRAZOLE;

ADULT; AGED; ARTICLE; BLOATING; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FLATULENCE; GASTROESOPHAGEAL REFLUX; HUMAN; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; NAUSEA; PAIN ASSESSMENT; PRIORITY JOURNAL; QUESTIONNAIRE; SCORING SYSTEM; SYSTEMIC SCLEROSIS; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; AGED, 80 AND OVER; ENZYME INHIBITORS; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; MALE; MIDDLE AGED; PATHOLOGY; PROTON-TRANSLOCATING ATPASES; QUESTIONNAIRES; SCLERODERMA, SYSTEMIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 70350330501     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. YOUNG MA, ROSE S, REYNOLDS JC: Gastrointestinal manifestations of scleroderma. Rheum Dis Clin North Am 1996; 22: 797-823.
2. DIMENAS E: Methodological aspects of evaluation of quality of life in upper gastrointestinal disease. Scand J Gastroenterol 1993; 28 (Suppl. 199): 18-21.
3. KUSANO T, SHIMOYAMA Y, SUGIMOTO S et al.: Development and evaluation of FSSG; frequency scale for the symptoms of GERD. J Gastroenterol 2004; 39: 888-891
4. CARLSSON R, DENT J, BOLLING-STERNEVALD E et al.: The usefulness of a structured questionnaire in the assessment of symptomatic gastroesophageal reflux disease. Scand J Gastroenterol 1998; 33: 1023-1029
5. LEROY EC, BLACK C, FLEISCHMAJER R et al.: Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-205
6. SUBCOMMITTEE FOR SCLERODERMA. CRITERIA OF THE AMERICAN RHEUMATISM ASSOCIATION DIAGNOSTIC AND THERAPEUTIC CRITERIA COMMITTEE: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-590
7. TAKEHARA K, SATO S: The classification of pathogenesis and the development of therapy in systemic sclerosis: the classification of severity and the guideline for treatment (2004). A research project for systemic sclerosis supported by Japanese Ministry of Health and Welfare; 2004.
8. MORITA Y, MURO Y, SUGIURA K et al.: Results of the health assessment questionnaire for Japanese patient with systemic sclerosis - measuring functional impairment in systemic sclerosis versus other connective tissue diseases. Clin Exp Rheumatol 2007; 25: 367-372
9. CHIBA N, DE GARA CJ, WILKINSON JM, RICHARD H: Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease; a meta-analysis. Gastroenterology 1997; 112: 1798-1810
10. SAITO T, FUKUSHIMA Y, OTSUKA H et al.: Effect of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment Pharmacol Ther 2002; 16: 1811-1817
11. ISHIZAKIT, HORAI Y: Cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther 1999; 13: 27-36. (Pubitemid 29389409)
12. ADACHI K, KATUBET, KAWAMURA A et al.: CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther 2000; 14: 1259-1266
13. WEINSTEIN WM, KADELL BM: The gastrointestinal tract in systemic sclerosis. In: CLEMENTS PJ, FURST DE, (Eds.) Systemic Sclerosis. Philadelphia: Lippincott Williams & Wilkins 2004: 293-308.
14. MIYAMOTO M HARUMA K, TAKEUCHI K, KUWABARA M: Frequency scale for symptoms of gastroesophageal reflux disease predicts the need for addition of prokinetic to proton pump inhibitor therapy. J Gastroenterol Hepatol 2008; 23: 746-751
15. ADACHI K, KOMAZAWA Y, FUJISHIRO H et al.: Nocturnal gastric acid breakthrough during the administration of rabeprazole and ranitidine in Helicobacter pylori-negative subjects: effects of different regimens. J Gastroenterol 2003; 38: 830-835